Cozad Asset Management Inc. cut its holdings in Becton Dickinson and Co (NYSE:BDX) by 4.2% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 2,509 shares of the medical instruments supplier’s stock after selling 109 shares during the quarter. Cozad Asset Management Inc.’s holdings in Becton Dickinson and were worth $627,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of BDX. IMS Capital Management bought a new stake in shares of Becton Dickinson and during the 3rd quarter worth approximately $29,000. Oregon Public Employees Retirement Fund raised its stake in shares of Becton Dickinson and by 22,485.4% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 6,574,612 shares of the medical instruments supplier’s stock worth $29,000 after purchasing an additional 6,545,502 shares in the last quarter. RPG Investment Advisory LLC bought a new stake in shares of Becton Dickinson and during the 1st quarter worth approximately $32,000. Nalls Sherbakoff Group LLC bought a new stake in shares of Becton Dickinson and during the 4th quarter worth approximately $34,000. Finally, Aspire Private Capital LLC bought a new stake in shares of Becton Dickinson and during the 4th quarter worth approximately $39,000. Institutional investors and hedge funds own 84.87% of the company’s stock.

BDX has been the topic of a number of analyst reports. Zacks Investment Research upgraded Becton Dickinson and from a “sell” rating to a “hold” rating in a research note on Wednesday, April 10th. Raymond James dropped their price objective on Becton Dickinson and from $290.00 to $280.00 and set a “strong-buy” rating on the stock in a research note on Tuesday, March 19th. Citigroup dropped their price objective on Becton Dickinson and from $279.00 to $256.00 and set a “buy” rating on the stock in a research note on Wednesday, January 2nd. Piper Jaffray Companies increased their price target on Becton Dickinson and to $274.00 and gave the company an “overweight” rating in a research note on Tuesday, February 5th. Finally, Morgan Stanley dropped their price target on Becton Dickinson and from $265.00 to $240.00 and set an “equal weight” rating on the stock in a research note on Wednesday, January 2nd. One analyst has rated the stock with a sell rating, five have given a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $256.25.

In other news, CEO Vincent A. Forlenza sold 8,309 shares of the stock in a transaction on Friday, March 15th. The stock was sold at an average price of $255.13, for a total transaction of $2,119,875.17. Following the sale, the chief executive officer now directly owns 222,785 shares of the company’s stock, valued at approximately $56,839,137.05. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Vincent A. Forlenza sold 11,340 shares of the stock in a transaction on Monday, February 25th. The stock was sold at an average price of $250.40, for a total value of $2,839,536.00. Following the sale, the chief executive officer now directly owns 227,250 shares in the company, valued at $56,903,400. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 29,684 shares of company stock worth $7,518,574. Insiders own 0.12% of the company’s stock.

BDX opened at $227.89 on Friday. Becton Dickinson and Co has a 1-year low of $208.62 and a 1-year high of $265.87. The company has a current ratio of 0.97, a quick ratio of 0.62 and a debt-to-equity ratio of 0.83. The firm has a market capitalization of $61.32 billion, a P/E ratio of 20.70, a price-to-earnings-growth ratio of 1.74 and a beta of 1.21.

Becton Dickinson and (NYSE:BDX) last issued its quarterly earnings data on Tuesday, February 5th. The medical instruments supplier reported $2.70 EPS for the quarter, beating analysts’ consensus estimates of $2.58 by $0.12. Becton Dickinson and had a return on equity of 14.65% and a net margin of 5.69%. The firm had revenue of $4.16 billion for the quarter, compared to analyst estimates of $4.10 billion. During the same period in the prior year, the firm posted $2.48 EPS. The company’s revenue for the quarter was up 35.1% on a year-over-year basis. As a group, equities analysts expect that Becton Dickinson and Co will post 12.08 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which was paid on Friday, March 29th. Shareholders of record on Friday, March 8th were issued a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a yield of 1.35%. The ex-dividend date of this dividend was Thursday, March 7th. Becton Dickinson and’s dividend payout ratio is 27.97%.

ILLEGAL ACTIVITY WARNING: “Becton Dickinson and Co (BDX) Shares Sold by Cozad Asset Management Inc.” was originally published by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this story can be viewed at https://www.dailypolitical.com/2019/04/20/becton-dickinson-and-co-bdx-shares-sold-by-cozad-asset-management-inc.html.

About Becton Dickinson and

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Further Reading: Trading based on a resistance level

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.